Backed by a pioneer in BiTE tech, Harpoon marks a course for an IPO and an early display of potential
Can a next-gen BiTE devised by a pioneer in the field attract investors into an oncology IPO based almost entirely on mouse data? Harpoon Therapeutics plans to find that out in early 2019.
The biotech has filed an $86 million IPO, just a few months after raising $70 million in its latest venture round. The company also spelled out some of the details in its alliance with AbbVie, which came with a $17 million upfront and hundreds of millions more in milestones on the table.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.